Real Talk Capital’s Gilead Sciences GILD Stock Holding History

Real Talk Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$328K	Sell	2,356 -86	-4%	-$12K	0.31%	66
2025 Q4	$300K	Buy	+2,442	New	+$297K	0.3%	73

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Real Talk Capital's GILD Position: Q1 2026 in Review

Real Talk Capital reduced its Gilead Sciences (GILD) stake by 3.5% in Q1 2026, selling an estimated $12K and leaving 2,356 shares worth $328K. The position accounts for 0.31% of the portfolio, ranked #66.

Real Talk Capital first reported a position in GILD in Q4 2025 and has held it in 2 quarters since. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Real Talk Capital held 2,356 shares of Gilead Sciences worth $328K as of Q1 2026.
Real Talk Capital sold 86 Gilead Sciences shares in Q1 2026, an estimated $12K.
Gilead Sciences made up 0.31% of Real Talk Capital's portfolio in Q1 2026, its #66 holding.
Real Talk Capital first reported a position in Gilead Sciences in Q4 2025 and has held it in 2 quarters since.
2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Real Talk Capital's 13F filing for Q1 2026, filed 15 May 2026.